About Us

Our story

Headquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized cell therapies. We are developing autologous (the patient’s own) induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD).

As a leading iPSC platform company, we combine stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. We have developed a best-in-class platform to create and characterize pluripotent-derived cell medicines, including in-house bioinformatics, manufacturing and QC.

Our history

The company was founded in 2018 by a group of research scientists from Dr. Jeanne Loring’s lab at The Scripps Research Institute, and a group of patient advocates from Summit for Stem Cell, who believed in the promise of early research demonstrating the potential benefits of cell replacement for Parkinson’s disease.

Our mission and vision

iStock 1181228916 web 1

Our Mission is to develop and deliver iPSC-derived autologous cell replacement therapies for patients with unmet medical needs, beginning with Parkinson’s disease.

And our Company’s Vision is to be the leading developer of autologous iPSC-based therapies.

How do we live our values?

  • Patient-Centered – We carry a strong sense of responsibility to patients and make decisions to positively impact patient outcomes.
  • Integrity – We are transparent with our intentions, and act like owners, taking responsibility for our results and our behavior.
  • Collaboration – We work with each other, our investors and our partners to achieve collective success.
  • Innovation – We push ourselves and existing boundaries to develop new technologies and solutions.
  • Performance – We focus on delivering high quality results with speed and efficiency.
Forest of Aspen Trees

What we have achieved

iStock 172646513 web
  • We are a preclinical private company, performing IND-enabling studies with our lead product (ANPD001) targeting sporadic Parkinson’s disease, and preparing for our first IND file.
  • We leverage proprietary AI-based genomics tools for comprehensive quality control which allows for a reduction in the time and cost of the manufacturing process required to produce a safe, reproducible, and personalized cell therapy.
  • We have performed in vitro and in vivo studies demonstrating that our manufacturing protocol reliably produces A9-like dopamine releasing neurons when examined both physiologically and functionally.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.